|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2000-1-6
|
|
pubmed:abstractText |
We devised two short peptides corresponding to amino acids 211-221 of human Cdc25C fused with a part of HIV1-TAT. These peptides inhibited hChk1 and Chk2/HuCds1 kinase activity in vitro and specifically abrogated the G2 checkpoint in vivo. These peptides sensitized p53-defective cancer cell lines to DNA-damaging agent to death without obvious cytotoxic effect on normal cells. Our results clearly indicate that the specific abrogation of the cell cycle G2 checkpoint is a feasible strategy for cancer therapy, and hChk1 and Chk2/HuCds1 are proper targets for that purpose.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CDC25C protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cell Cycle Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Gene Products, tat,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/cdc25 Phosphatases,
http://linkedlifedata.com/resource/pubmed/chemical/checkpoint kinase 2,
http://linkedlifedata.com/resource/pubmed/chemical/histone H1 kinase,
http://linkedlifedata.com/resource/pubmed/chemical/tat Gene Products, Human...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0008-5472
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
59
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5887-91
|
|
pubmed:dateRevised |
2011-11-2
|
|
pubmed:meshHeading |
pubmed-meshheading:10606229-Amino Acid Sequence,
pubmed-meshheading:10606229-Cell Cycle,
pubmed-meshheading:10606229-Cell Cycle Proteins,
pubmed-meshheading:10606229-Cell Survival,
pubmed-meshheading:10606229-DNA Damage,
pubmed-meshheading:10606229-G2 Phase,
pubmed-meshheading:10606229-Gene Products, tat,
pubmed-meshheading:10606229-HIV-1,
pubmed-meshheading:10606229-Humans,
pubmed-meshheading:10606229-Jurkat Cells,
pubmed-meshheading:10606229-Peptide Fragments,
pubmed-meshheading:10606229-Protein Kinases,
pubmed-meshheading:10606229-Protein-Serine-Threonine Kinases,
pubmed-meshheading:10606229-Recombinant Fusion Proteins,
pubmed-meshheading:10606229-cdc25 Phosphatases,
pubmed-meshheading:10606229-tat Gene Products, Human Immunodeficiency Virus
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation.
|
|
pubmed:affiliation |
Department of Molecular Genetics, Nagoya City University School of Medicine, Nagoya, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
